XYLYX BIO releases highly physiologic 2D substrates for improved antifibrotic drug discovery
NEW YORK, Aug. 26, 2020 /PRNewswire/ — New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput…
Comments Off on XYLYX BIO releases highly physiologic 2D substrates for improved antifibrotic drug discovery